Thursday , 26 May 2022

Psilocybin (Magic Mushroom) Drug Stock Performances YTD

Of the 35 companies involved in clinical stage research of one or more of 10 different psychedelic substances (see recent article 10 Psychedelic Substances Now Being Researched By 35 Companies20 of them are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. Here’s a list of those 20 companies and how well their stocks have performed YTD.

An original article by Lorimer Wilson, Managing Editor of munKNEE.com – Your KEY To Making Money!

What Is Psilocybin?

Psilocybin is the most widely-researched psychedelic substance today due to its minimal toxicity, non-addictive nature and powerful medicinal effect of generating new neural pathways that allow different regions within the brain to communicate in new and more effective ways. As such, it is likely to become the first psychedelic drug to be de-scheduled by a major government and legalized for medicinal use.

  • A recent poll in Canada shows that nearly 80% of the population favor legalizing psilocybin for medicinal use and, to that end, Health Canada has already been granting special exemptions to allow patients with critical healthcare needs to be treated with psilocybin-based therapies.
  • In the U.S., while psilocybin enjoys rapidly increasing grassroots support at the local and even state level, psychedelics research remains blocked at the federal level.
  • Legal use and commercialization of psilocybin may advance much faster in the EU and UK via their “real-world evidence” pathway to drug approval that advances drugs that are proven safe substances, a category into which psilocybin fits.

Larger Cap Companies Involved In Psilocybin Research and Their Performances YTD

  • Compass Pathways (CMPS); Mkt. Cap: $1.33B; -33.2% YTD 
  • Cybin Inc. (CYBN); Mkt. Cap: $372M; +101.3% YTD
  • Mind Medicine (MNMD); Mkt. Cap: $1.01B; -9.8% YTD  
  • Mydecine (MYCOF); Mkt. Cap: $90M; +8.6% YTD
  • Average Mkt. Cap: $700.5M

Nano Cap Companies Involved In Psilocybin Research

In addition 16 much smaller market cap companies – Aion Therapeutics  (AION), Bright Minds Biosciences (DRUG), Creso Pharma (COPHF) through its subsidiary Haluvenex Life Sciences, Filament Health (NEO:FH), HAVN Life Sciences (HAVLF), M2Bio Sciences (WUHN), Mindset Pharma (MSSTF),  Neonmind Biosciences (NEON), Nova Mentis (NOVA), PsyBio Therapeutics  (PSYBF), Revive Therapeutics (RVVTF), Silo Wellness (SILO),  Tryp Therapeutics (TRUFF), Optimi Health (OPTHF), Psyence Group (PSYG) and Wesana Health (WESA) – are also doing research clinical-stage research using psilocybin. Their average market capitalization is $41M and they are -28.7% YTD.

A Few Last Words: 

  • Click the “Like” button at the top of the page if you found this article a worthwhile read as this will help us build a bigger audience.
  • Comment below if you want to share your opinion or perspective with other readers and possibly exchange views with them.
  • Register to receive our free Market Intelligence Report newsletter (sample here) in the top right hand corner of this page.
  • Join us on Facebook to be automatically advised of the latest articles posted and to comment on any of them.
 munKNEE.com has joined eResearch.com to provide individual company research articles and specific stock recommendations in addition to munKNEE’s more general informative articles on the economy, the markets, and gold, silver, cannabis and psychedelic drug stock investing.
Check out eResearch. If you like what you see then…